Cancer Commun: Clinical characteristics and prognosis analysis of Chinese KRAS mutant non-small cell lung cancer patients after chemotherapy

The RAS gene is one of the most common oncogenes in human cancers, with significantly different mutation frequencies

The RAS gene is one of the most common oncogenes in human cancers, with significantly different mutation frequencies

We reviewed 2016 Nian 1 month to 2020 Nian 10 undergo genetic testing during the month of Shandong Cancer Hospital in 5180 patients with non-small cell lung cancer ( either newly issued or relapse ) patient data

We reviewed 2016 Nian 1 month to 2020 Nian 10 undergo genetic testing during the month of Shandong Cancer Hospital in 5180 patients with non-small cell lung cancer ( either newly issued or relapse ) patient data

Of the 5180 NSCLC patients screened , 477 had RAS mutations and 471 had KRAS mutations

Among 1239 patients undergoing ARMS-PCR testing

The study analyzed the RAS mutation subtypes of 372 patients tested for NGS

RASt mutation distribution

Next, the study will compare the efficacy of first-line pemetrexed + platinum-based chemotherapy in KRAS mutant and KRAS wild-type patients

Next, the study will compare the efficacy of first-line pemetrexed + platinum-based chemotherapy in KRAS mutant and KRAS wild-type patients

KRAS mutation and wild prognosis

Using univariate and multivariate analysis, platelet/lymphocyte ratio (PLR) (hazard ratio [HR] = 2.

Using univariate and multivariate analysis, platelet/lymphocyte ratio (PLR) (hazard ratio [HR] = 2.

In this study, the KRAS mutation rate of patients tested by ARMS-PCR was 8.

In this study, patients with NSCLC were divided into 4 subtypes based on the characteristics of genomic changes, but no difference in survival between the subtypes was observed

Prognostic analysis of other subgroups

In summary, the KRAS mutation rate of Chinese NSCLC patients seems to be lower than that of whites, and the rate of KRAS G12C mutations does not exceed 30%
.
Compared with KRAS wild-type patients, KRAS mutant patients had worse PFS after pemetrexed+platinum treatment
.
Finally, chemotherapy combined with immunotherapy can improve the survival rate of patients with KRAS mutant lung adenocarcinoma
.

In summary, the KRAS mutation rate of Chinese NSCLC patients seems to be lower than that of whites, and the rate of KRAS G12C mutations does not exceed 30%
.
Compared with KRAS wild-type patients, KRAS mutant patients had worse PFS after pemetrexed+platinum treatment
.
Finally, chemotherapy combined with immunotherapy can improve the survival rate of patients with KRAS mutant lung adenocarcinoma
.
The KRAS mutation rate of Chinese NSCLC patients seems to be lower than that of whites, and the proportion of KRAS G12C mutations does not exceed 30%
.
Compared with KRAS wild-type patients, KRAS mutant patients had worse PFS after pemetrexed+platinum treatment
.
Finally, chemotherapy combined with immunotherapy can improve the survival rate of patients with KRAS mutant lung adenocarcinoma
.
The KRAS mutation rate of Chinese NSCLC patients seems to be lower than that of whites, and the proportion of KRAS G12C mutations does not exceed 30%
.
Compared with KRAS wild-type patients, KRAS mutant patients had worse PFS after pemetrexed+platinum treatment
.
Finally, chemotherapy combined with immunotherapy can improve the survival rate of patients with KRAS mutant lung adenocarcinoma
.

Original source:

Original source:

Yawen Zheng, Qinghua Lai, Hanxi Zhao, et al.
Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy.
Cancer Communications.
2021;1–5.
DOI: 10.
1002/cac2.
12227.

Yawen Zheng, Qinghua Lai, Hanxi Zhao, et al.
Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy.
Cancer Communications.
2021;1–5.
DOI: 10.
1002/cac2.
12227.


In This message